Profiel
Nic G.
Scalfarotto held former positions as Vice President-Regulatory Affairs at Momenta Pharmaceuticals, Inc., Senior Vice President-Regulatory Affairs at Aegerion Pharmaceuticals, Inc. and Kura Oncology, Inc., and VP-Regulatory Affairs & Program Management at X4 Pharmaceuticals, Inc. He obtained an undergraduate degree from Seton Hall University and a doctorate degree from Alma Mater Studiorum - Università di Bologna.
Eerdere bekende functies van Nic G. Scalfarotto
| Bedrijven | Functie | Einde |
|---|---|---|
| KURA ONCOLOGY, INC. | Algemeen Adviseur | - |
| X4 PHARMACEUTICALS, INC. | Algemeen Adviseur | - |
| AEGERION PHARMACEUTICALS, INC. | Algemeen Adviseur | - |
| MOMENTA PHARMACEUTICALS, INC. | Algemeen Adviseur | - |
Opleiding van Nic G. Scalfarotto
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that discovers and develops novel biologic therapies for the treatment of rare immune-mediated diseases | Health Technology |
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for hyperlipidemia and metabolic diseases | Health Technology |
Kura Oncology, Inc.
Kura Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Seton Hall University
Seton Hall University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alma Mater Studiorum - Università di Bologna
Alma Mater Studiorum - Università di Bologna Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
















